Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

Chaayinaan naannoo Taayiwaanitti shaakala waraanaa naannoolee ijoo odola kanaa to'achuu fakkaatu gaggeessaa jirti. Kunis ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to ...

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug ...

As of Wednesday, December 24, Agios Pharmaceuticals, Inc.’s AGIO share price has surged by 16.31%, which has investors questioning if this is right time to sell.

Analysts are intrested in these 5 stocks: ( ($IBIO) ), ( ($RLMD) ), ( ($SEE) ), ( ($OLLI) ) and ( ($IVVD) ). Here is a breakdown of their recent ...